Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HGH HoldingsSGX:5GZ EBITDA Margin % is 13.84% as of Dec. 2025, which is 25% above its 10-year median of 11.06. The stock has 2 warning signs investors should review. Among 3,031 Industrial Products companies, HGH Holdings ranks better than 75.59% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. HGH Holdings's EBITDA for the
six
months ended in Dec. 2025 was S$4.22 Mil. HGH Holdings's Revenue for the
six
months ended in Dec. 2025 was S$30.51 Mil. Therefore, HGH Holdings's EBITDA margin for the quarter that ended in Dec. 2025 was 13.84%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HGH Holdings EBITDA Margin % Related Terms
HGH Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HGH Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:5GZ vs VRT, BE, HUBB: EBITDA Margin % Comparison
For the Electrical Equipment & Parts subindustry, HGH Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HGH Holdings EBITDA Margin % vs Industrial Products Industry
For the Industrial Products industry and Industrials sector, HGH Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HGH Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HGH Holdings (SGX:5GZ) has a EBITDA Margin % of 13.84% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HGH Holdings and its competitors. This is 25% above median its historical median of 11.06. According to the industry distribution chart, HGH Holdings ranks #740 out of 3031 companies in the Industrial Products industry, placing it in the top 24.4%.
Is HGH Holdings' EBITDA Margin % too high?
HGH Holdings' current EBITDA Margin % of 13.84% is 25% above median its 10-year median of 11.06. The Industrial Products industry median EBITDA Margin % is 9.45. HGH Holdings' value of 13.84% is 46.5% above this industry median. Based on the distribution chart, HGH Holdings ranks #740 out of 3031 companies in the Industrial Products industry, which is in the top quartile — a strong position relative to peers.
How does HGH Holdings' EBITDA Margin % compare to VRT and BE?
According to the Industrial Products industry distribution chart, HGH Holdings ranks #740 out of 3031 companies for EBITDA Margin %. This places HGH Holdings in the top 24% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 9.45. HGH Holdings' value of 13.84% is 46.5% above this benchmark. While the company's 10-year median is 11.06 vs. the industry median of 9.45, HGH Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for an Industrial Products company?
The median EBITDA Margin % among Industrial Products companies is 9.45, based on 3,031 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HGH Holdings's current EBITDA Margin % of 13.84% is 46.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HGH Holdings and its competitors. For the Industrial Products industry, the median EBITDA Margin % is 9.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HGH Holdings's current EBITDA Margin % is 13.84%, which is 25% above median its own 10-year median of 11.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HGH Holdings stock overvalued right now?
Based on GuruFocus' analysis, HGH Holdings (SGX:5GZ) is currently considered Possible Value Trap. The stock's GF Value™ is S$0.04, compared to a current price of S$0.02 — trading 62.5% below its estimated fair value. The current EBITDA Margin % is 13.84%, which is 25% above median its 10-year median of 11.06 and 46.5% above the Industrial Products industry median of 9.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HGH Holdings (SGX:5GZ), the current EBITDA Margin % is 13.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HGH Holdings Ltd, through its subsidiaries, is engaged in the supply and manufacturing of ready-mix concrete products; supply of precast concrete products; providing one-stop high value-added general warehousing and logistics services, industrial, office space for engineering, manufacturing, industrial training, and workers' dormitory facilities; and providing underground cable installation and road reinstatement services. Its segments include leasing and service income, the Manufacturing of Precast Concrete products, the Supply and Manufacturing of Ready-Mix Concrete products; and the provision of Underground Cable Installation and Road Reinstatement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:5GZ has been successfully added to your 
